Technology | Magnetic Resonance Imaging (MRI) | October 12, 2016

FDA Clears Icometrix' Image Quantification Software to Monitor Neurological Disorders

Software quantifies key features of MRI brain scans to help monitor brain changes over time

icometrix, icobrain, MRI brain scans, longitudinal measurements, RSNA 2016, FDA clearance

October 12, 2016 — The health tech company Icometrix obtained 510(k) clearance in September from the U.S. Food and Drug Administration (FDA) for their image quantification software, icobrain. The software quantifies key features of clinical magnetic resonance imaging (MRI) brain scans, which enable clinicians to monitor how their patient's brain changes over time.

As the only software currently available that has been scientifically validated and clinically approved for longitudinal measurements, according to the company, icobrain offers clinicians unrivalled access to unique information about disease progression and the effect of treatment upon brain structure.

"MRI biomarkers are becoming of vital importance in the clinical care path for various pathologies, including neurological disorders such as multiple sclerosis, traumatic brain injury and stroke. It is of paramount importance that the biomarker measurements are extremely reproducible and sensitive enough to detect relevant clinical changes", said Max Wintermark, M.D., professor of radiology and chief of neuroradiology at the Stanford University Medical Center. "The icometrix methods have been published in several scientific journals and validated by top centers worldwide, demonstrating the accuracy that is needed to translate measures from a research setting to routine clinical practice," Wintermark added.

Icometrix' analysis services help radiologists and physicians worldwide to improve and personalize the care of patients with a neurological disorder, such as multiple sclerosis, traumatic brain injury or dementia. Accessing the U.S. market is an important step and will lead to more evidence-based medicine by bringing automated MRI reports into clinical practice.

For more information: www.icometrix.com

Related Content

ASG well positioned for growth as healthcare marketplace continues to evolve 

Allan Klotsche

News | Radiology Imaging | November 24, 2020
November 24, 2020 — Alpha Source Group (ASG), a comprehensive next-generation services partner, has named...
New multimodality virtual imaging command center enables real-time, remote collaboration to broaden expertise between technologists, radiologists and imaging operations teams across multiple sites via private, secure telepresence capabilities
News | Information Technology | November 24, 2020
November 24, 2020 — Philips announced commercial launch of the industry’s first vendor-neutral, multimodality, radiol
Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in advanced visualization for nearly two decades and a preeminent provider of zero-footprint, cloud-based imaging SDKs, today announced that it will be showcasing the continued expansion of its artificial intelligence product portfolio together with Fovia’s advanced imaging solutions at the first Virtual Radiology Society of North America (RSNA) Conference, November 29 - December 5.
News | Artificial Intelligence | November 24, 2020
November 24, 2020 — Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in...
1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well

1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well as elevated Lac. B, A patient with COVID-19 after recent PEA cardiac arrest with subtle FLAIR hyperintense white matter changes also shows elevated Cho/Cr and decreased NAA/Cr ratios. However, these derangements are less severe than in the patient in A. There is no clear elevation of Lac. C, A patient with COVID-19 without encephalopathy or recent severe hypoxia has normal Cho/Cr, with mildly decreased NAA/Cr and no lactate elevation. Cho, Choline; NAA, N-Acetyl-Aspartate; mI, Myo-Inositol; Lac, Lactate; Glx, Glutamate + Glutamine. Image courtesy of AJNR

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — One of the first spectroscopic imaging-based studies of neurological injury in...
SyntheticMR, an innovative software solutions company for magnetic resonance imaging (MRI) announced today the company filed a 510(k) submission for its musculoskeletal solutions package, SyMRI MSK.
News | Magnetic Resonance Imaging (MRI) | November 17, 2020
November 17, 2020 — SyntheticMR, an innovative software solutions company for...
Honoring essential healthcareprofessionals, Nov. 8-14
News | Radiology Imaging | November 09, 2020
November 9, 2020 — As COVID-19 continues to spre
This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

Feature | Magnetic Resonance Imaging (MRI) | October 29, 2020
October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a ver